This webinar is part 1 in a 3-part curriculum.
Program Description
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and
for many years, treatment options were primarily limited to surgery, radiation,
and cytotoxic chemotherapy. However, the advent of precision medicine, which
involves tailoring therapies to the specific genetic and molecular profile of a
patient's tumor, has led to improved survival outcomes. This webinar is the
first in a 3-part series exploring the evolving role of precision medicine in
NSCLC. In this webinar, attendees will become familiar with the impact of
precision medicine and different molecular testing methods used to identify
specific biomarkers in NSCLC. The discussion will center on the various
targetable mutations that drive NSCLC, exploring how the presence of these
biomarkers can guide treatment selection and improve efficacy. A key focus of
this session will be the clinical significance of these biomarkers, current
guideline recommendations for testing, and the critical importance of timely
and accurate testing as well as consequences of delayed or inaccurate testing
that oncology pharmacists can manage and mitigate in practice, including
suboptimal treatment choices, increased risk of toxicity, and reduced
therapeutic efficacy. This webinar will provide a crucial foundation for
understanding the subsequent components of the program, which will build on
these concepts to explore advanced topics in NSCLC treatment.
Target Audience: Oncology pharmacists
Type
of Activity: Application
Release date: October 10, 2025
Expiration date: October 10, 2026
Learner level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify common and uncommon biomarkers in non-small cell lung cancer (NSCLC) and their clinical significance
- Interpret current guideline recommendations for biomarker, mutational, and genomic testing in NSCLC
- Examine how inaccurate or delayed biomarker testing can lead to suboptimal treatment selection, increased toxicity, and reduced efficacy
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here